JAB-23E73 not checked

Jacobio Pharmaceuticals Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Advanced Solid Tumor, Advanced Solid Tumors, Metastatic Pancreatic Ductal Adenocarcinoma
Main trialPhase 1/2
“This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.”In the company’s words, NCT06959615 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumor

All 2439 drugs for Advanced Solid Tumor

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 31 Dec 2026 A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/2Recruiting Nov 2028 JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/2Recruiting 31 Dec 2029 Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow JAB-23E73

Following is part of Solo: you see every change to JAB-23E73 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in